CJC-1295
About
About CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
Science
Mechanism of Action
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The DAC modification allows binding to albumin in the bloodstream, significantly extending the half-life. Downstream effects include increased hepatic IGF-1 production, enhanced protein synthesis, lipolysis, and improved cellular repair mechanisms.
Dosing
Typical Protocol
CJC-1295 with DAC: 1–2 mg once or twice weekly subcutaneously. CJC-1295 without DAC (Modified GRF 1-29): 100–300 mcg before bed, combined with Ipamorelin 100–300 mcg. Most protocols run for 3–6 month cycles with periodic IGF-1 monitoring. Administered subcutaneously, typically before sleep to align with natural GH pulsation.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Compare verified providers offering CJC-1295
All 17 audited providers, ranked by Vial Check by default. Click any column to sort.
Compound comparisons
Compare CJC-1295
CJC-1295 set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.